Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Feb 14, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q4 2016. Go to the latest filing (Q3 2026)

7.6B USDQ4 2016
Total value of stock positions
7.6B USD
Positions
42
Share of the ten largest
72.4%

The ten largest positions Q4 2016

  1. Cheniere Energy Inc 11.8%▼ −22.0%
  2. Viasat Inc 11.5%▲ +14.1%
  3. Synchrony Financial 9.9%▲ +17.6%
  4. Allergan PLC 9.5%▲ +71.5%
  5. Twenty First Centy Fox Inc 7.1%▲ +50.1%
  6. Pbf Energy Inc 5.8%unchanged
  7. Dell Technologies 4.8%unchanged
  8. Antero Res Corp 4.5%unchanged
  9. Theravance Biopharma Inc 3.9%▲ +26.2%
  10. Northstar Asset Mgmt Group I 3.7%▲ +88.7%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q4 2016

Positions Q4 2016 per 13F filing, 42 of 42
Symbol Weight Shares Reported value Change Held since
Viasat Inc 11.5% 13,158,137 871.3M USD +14.1% increased Q2 2013 or earlier 15 quarters
American Intl Group Inc 0.8% 2,594,317 60.9M USD unchanged Q2 2013 or earlier 15 quarters
Novagold Res Inc 0.6% 9,500,000 43.3M USD unchanged Q2 2013 or earlier 15 quarters
Citigroup Inc 0.1% 62,903,207 9.6M USD −38.7% reduced Q2 2013 or earlier 15 quarters
Pbf Energy Inc 5.8% 15,724,175 438.4M USD unchanged Q3 2013 14 quarters
Cheniere Energy Inc 11.8% 21,726,340 900.1M USD −22.0% reduced Q1 2014 12 quarters
Keryx Biopharmaceuticals Inc 2.0% 25,791,678 151.1M USD unchanged Q1 2014 12 quarters
Theravance Biopharma Inc 3.9% 9,273,991 295.7M USD +26.2% increased Q2 2014 11 quarters
Antero Res Corp 4.5% 14,505,881 343.1M USD unchanged Q3 2014 10 quarters
Veritiv Corp 2.2% 3,044,385 163.6M USD unchanged Q3 2014 10 quarters
Forward Pharma A/S 1.1% 5,367,300 80.5M USD unchanged Q4 2014 9 quarters
Atara Biotherapeutics Inc 1.0% 5,359,632 76.1M USD unchanged Q4 2014 9 quarters
Paratek Pharmaceuticals Inc 0.4% 2,044,498 31.5M USD unchanged Q4 2014 9 quarters
Twenty First Centy Fox Inc 7.1% 19,137,469 536.6M USD +50.1% increased Q3 2015 6 quarters
Twenty First Centy Fox Inc 2.6% 7,278,100 198.3M USD unchanged Q3 2015 6 quarters
RUN Sunrun 0.2% 2,848,082 15.1M USD unchanged Q3 2015 6 quarters
Allergan PLC 9.5% 3,432,603 720.9M USD +71.5% increased Q1 2016 4 quarters
Innoviva Inc 2.1% 14,931,483 159.8M USD unchanged Q1 2016 4 quarters
Liberty Media Corp Delaware 0.8% 2,994,010 61.6M USD unchanged Q2 2016 3 quarters
Credit Accep Corp Mich 0.7% 244,400 53.2M USD +144.4% increased Q2 2016 3 quarters
Liberty Media Corp Delaware 0.2% 800,000 16.4M USD unchanged Q2 2016 3 quarters
SYF Synchrony Financial 9.9% 20,665,000 749.5M USD +17.6% increased Q3 2016 2 quarters
DELL Dell Technologies 4.8% 6,652,459 365.7M USD unchanged Q3 2016 2 quarters
Northstar Asset Mgmt Group I 3.7% 18,705,000 279.1M USD +88.7% increased Q3 2016 2 quarters
Northstar Rlty Fin Corp 2.9% 14,577,134 220.8M USD +165.1% increased Q3 2016 2 quarters
Colony Cap Inc 1.9% 6,959,017 140.9M USD +56.5% increased Q3 2016 2 quarters
Conyers Pk Acquisition 0.5% 3,712,500 38.0M USD unchanged Q3 2016 2 quarters
Trilogy Metals Inc New < 0.1% 10,600,758 5.3M USD unchanged Q3 2016 2 quarters
Orexigen Therapeutics Inc < 0.1% 2,226,839 3.9M USD unchanged Q3 2016 2 quarters
Conyers Pk Acquisition < 0.1% 1,237,500 2.5M USD unchanged Q3 2016 2 quarters
MCK McKesson Corporation 1.8% 1,000,000 140.5M USD new Q4 2016 1 quarter
CAH Cardinal Health 1.0% 1,030,000 74.1M USD new Q4 2016 1 quarter
Syngenta AG 0.8% 745,136 58.9M USD new Q4 2016 1 quarter
Liberty Interactive Corp 0.7% 1,481,719 54.6M USD new Q4 2016 1 quarter
Chipmos Technologies Inc 0.7% 3,509,858 49.5M USD new Q4 2016 1 quarter
Gty Technology Holdings Inc 0.6% 4,400,000 46.2M USD new Q4 2016 1 quarter
Centennial Resource Dev Inc 0.6% 2,407,153 43.6M USD new Q4 2016 1 quarter
COR Cencora 0.5% 502,474 39.3M USD new Q4 2016 1 quarter
Saban Cap Acquisition Corp 0.3% 2,326,500 23.3M USD new Q4 2016 1 quarter
Cascadian Therapeutics Inc 0.2% 4,166,666 18.0M USD new Q4 2016 1 quarter
Liberty Expedia Holdings 0.2% 395,613 15.7M USD new Q4 2016 1 quarter
Saban Cap Acquisition Corp < 0.1% 1,163,250 1.1M USD new Q4 2016 1 quarter

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 72.4M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Inc principal 46.2M USD 38.4M USD
  • Theravance Biopharma Inc principal 30.0M USD 34.1M USD

Breakdown by sector

  • Financials 9.9%
  • Technology 4.8%
  • Health Care 3.3%
  • Industrials 0.2%
  • not in our coverage 81.8%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close